Use of a dna damaging agent and a ligand for the treatment of cancer
AssigneeMedvet Science Pty. Ltd.
InventorsMichael Paul Brown, Fares Al-Ejeh, Jocelyn Margaret Darby
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a metastatic neoplastic tumour in a localised manner by effecting the exposure of neoplastic cell intra-cellular molecules, preferably intra-nuclear molecules, suitable for use as a therapeutic target. The co-localisation of tumour cells and metastases to discrete tissue locations thereby renders the method of the present invention useful in terms of the delivery of bystander-based therapy.
Claims38
A method for the treatment of a neoplasm in a subject, said method comprising:
- (i) administering to said subject one or more DNA damaging agents for a time and under conditions sufficient to induce the damage of at least a subpopulation of neoplastic cells, wherein said cell damage is characterised by the exposure of intra-cellular molecules;
- and
- (ii) administering to said subject a ligand directed to one or more of said intra-cellular molecules, which ligand is associated with an effector mechanism, for a time and under conditions sufficient to downregulate the growth of viable bystander neoplastic cells.
A method for the treatment of a neoplastic condition in a subject, said method comprising:
- (i) administering to said subject one or more DNA damaging agents for a time and under conditions sufficient to induce the damage of at least a subpopulation of neoplastic cells, wherein said cell damage is characterised by the exposure of intra-cellular molecules;
- and
- (ii) administering to said subject a ligand directed to one or more of said intra-cellular molecules, which ligand is associated with an effector mechanism, for a time and under conditions sufficient to downregulate the growth of viable bystander neoplastic cells.
Use of:
- (i) one or more DNA damaging agents;
- and
- (ii) an intracellular molecule ligand associated with an effector mechanism
- in the manufacture of a medicament for the treatment of a neoplastic condition in a subject wherein
- (i) administering to said subject said DNA damaging agent induces the damage of at least a subpopulation of neoplastic cells, wherein said cell damage is characterised by the exposure of intra-cellular molecules;
- and
- (ii) administering to said subject said ligand induces the downregulation of growth of viable bystander neoplastic cells.
The method according to any one of claims 1-4 wherein the level of said intracellular molecule is increased upon exposure of said cell to said DNA damaging agent.
A pharmaceutical composition comprising a DNA damaging agent or an intracellular molecule ligand associated with an effector mechanism.
A kit comprising a DNA damaging agent and an intracellular molecule ligand associated with an effector mechanism.
Dependencies are inferred from the claim text.